Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.

@article{ArizaAriza2007DoseEO,
  title={Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.},
  author={Rafael Ariza-Ariza and Federico Navarro-Sarabia and Blanca Hern{\'a}ndez-Cruz and L Rodr{\'i}guez-Arboleya and Victoria Navarro-Comp{\'a}n and Juan R. de los Toyos},
  journal={Rheumatology},
  year={2007},
  volume={46 3},
  pages={529-32}
}
OBJECTIVE To estimate the proportion of rheumatoid arthritis (RA) patients on anti-tumour necrosis factor (anti-TNF) who require dose escalation. METHODS Systematic review of the scientific literature. Infliximab, etanercept and adalimumab studies in RA were considered. Primary outcome was the proportion of patients requiring dose escalation. American College Rheumatology (ACR) and Disease activity score (DAS) responses post-escalation were assessed when available. RESULTS From 1801… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…